[A23-30] Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V
Last updated 11.08.2023
Project no.:
A23-30
Commission:
Commission awarded on 03.04.2023 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma
- With Child-Pugh A or no hepatic cirrhosis: added benefit not proven
- With Child-Pugh B: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-07-03.
| Project no. | Title | Status |
|---|---|---|
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-98 | Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-97 | Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V | Commission completed |
| A25-96 | Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V | Commission completed |
| A24-87 | Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-86 | Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |